142 related articles for article (PubMed ID: 24045609)
1. Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma.
Thondam SK; Alusi S; O'Driscoll K; Gilkes CE; Cuthbertson DJ; Daousi C
Clin Neuropharmacol; 2013; 36(5):170-2. PubMed ID: 24045609
[TBL] [Abstract][Full Text] [Related]
2. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas.
Martinkova J; Trejbalova L; Sasikova M; Benetin J; Valkovic P
Clin Neuropharmacol; 2011; 34(5):179-81. PubMed ID: 21738024
[TBL] [Abstract][Full Text] [Related]
3. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
De Sousa SM; Chapman IM; Falhammar H; Torpy DJ
Endocrine; 2017 Feb; 55(2):618-624. PubMed ID: 27601019
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease.
Perez-Lloret S; Rey MV; Fabre N; Ory F; Spampinato U; Brefel-Courbon C; Montastruc JL; Rascol O
Clin Neuropharmacol; 2012; 35(6):261-5. PubMed ID: 23123689
[TBL] [Abstract][Full Text] [Related]
5. Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study.
Dogansen SC; Cikrikcili U; Oruk G; Kutbay NO; Tanrikulu S; Hekimsoy Z; Hadzalic A; Gorar S; Omma T; Mert M; Akbaba G; Yalin GY; Bayram F; Ozkan M; Yarman S
J Clin Endocrinol Metab; 2019 Jul; 104(7):2527-2534. PubMed ID: 30848825
[TBL] [Abstract][Full Text] [Related]
6. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
7. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.
Hamidianjahromi A; Tritos NA
Rev Endocr Metab Disord; 2022 Oct; 23(5):1089-1099. PubMed ID: 36125673
[TBL] [Abstract][Full Text] [Related]
8. Long term follow-up of Parkinson's disease patients with impulse control disorders.
Sohtaoğlu M; Demiray DY; Kenangil G; Ozekmekçi S; Erginöz E
Parkinsonism Relat Disord; 2010 Jun; 16(5):334-7. PubMed ID: 20223696
[TBL] [Abstract][Full Text] [Related]
9. Treating prolactinomas with dopamine agonists: always worth the gamble?
Noronha S; Stokes V; Karavitaki N; Grossman A
Endocrine; 2016 Feb; 51(2):205-10. PubMed ID: 26336835
[TBL] [Abstract][Full Text] [Related]
10. [Dopamine dysregulation syndrome in Parkinson's disease and restless legs syndrome].
Bayard S; Cochen De Cock V; Dauvillers Y
Geriatr Psychol Neuropsychiatr Vieil; 2011 Jun; 9(2):227-35. PubMed ID: 21690031
[TBL] [Abstract][Full Text] [Related]
11. Medication-related impulse control and repetitive behaviors in Parkinson's disease.
Voon V; Potenza MN; Thomsen T
Curr Opin Neurol; 2007 Aug; 20(4):484-92. PubMed ID: 17620886
[TBL] [Abstract][Full Text] [Related]
12. Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease.
Ahlskog JE
Physiol Behav; 2011 Jul; 104(1):168-72. PubMed ID: 21557955
[TBL] [Abstract][Full Text] [Related]
13. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study.
Bancos I; Nannenga MR; Bostwick JM; Silber MH; Erickson D; Nippoldt TB
Clin Endocrinol (Oxf); 2014 Jun; 80(6):863-8. PubMed ID: 24274365
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced impulse control disorders in Parkinson's disease.
Reiff J; Jost WH
J Neurol; 2011 May; 258(Suppl 2):S323-7. PubMed ID: 21560063
[TBL] [Abstract][Full Text] [Related]
16. The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome.
Dang D; Cunnington D; Swieca J
Clin Neuropharmacol; 2011; 34(2):66-70. PubMed ID: 21412200
[TBL] [Abstract][Full Text] [Related]
17. Optic chiasmal herniation--an under recognized complication of dopamine agonist therapy for macroprolactinoma.
Jones SE; James RA; Hall K; Kendall-Taylor P
Clin Endocrinol (Oxf); 2000 Oct; 53(4):529-34. PubMed ID: 11012580
[TBL] [Abstract][Full Text] [Related]
18. [Impulse control disorders in Parkinson's disease].
Joutsa J; Kaasinen V
Duodecim; 2013; 129(22):2351-8. PubMed ID: 24397147
[TBL] [Abstract][Full Text] [Related]
19. Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease.
Fenu S; Wardas J; Morelli M
Behav Pharmacol; 2009 Sep; 20(5-6):363-79. PubMed ID: 19724195
[TBL] [Abstract][Full Text] [Related]
20. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up.
Celik E; Ozkaya HM; Poyraz BC; Saglam T; Kadioglu P
Endocrine; 2018 Dec; 62(3):692-700. PubMed ID: 30206771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
